Sandbox: Kaposi 2: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Haytham Allaham (talk | contribs)
nocaptcha, Administrators
5,080 edits
No edit summary
Haytham Allaham (talk | contribs)
nocaptcha, Administrators
5,080 edits
No edit summary
Line 1: Line 1:
* The optimal therapy for Kaposi's sarcoma depends on multiple factors which include:<ref name="pmid22677687">{{cite journal| author=Fatahzadeh M| title=Kaposi sarcoma: review and medical management update. | journal=Oral Surg Oral Med Oral Pathol Oral Radiol | year= 2012 | volume= 113 | issue= 1 | pages= 2-16 | pmid=22677687 | doi=10.1016/j.tripleo.2011.05.011 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22677687  }} </ref>
* '''Local/regional therapy recommended for the management of Kaposi's sarcoma patients may include:'''
:* The anatomical location of the tumor
:* Surgical excision
:* The specific variant of Kaposi's sarcoma
:* Cryotherapy
:* The rate of distribution and progression of Kaposi's sarcoma lesions
:* Sclerotherapy
:* The patients clinical presentation
:* Intralesional vinca-alkaloids, bleomycin, and interferon-alpha
:* The efficacy and potential side effects of therapy
:* Topical 0.1% alitretinoin
:* The presence or absence of HIV infection
:* Imiquimod cream
:* The degree of immune suppression,
:* Radiotherapy
:* The presence of other comorbidities
:* Laser therapy
:* The degree of host immune competence
:* The preference and prognosis of the patients


* Management strategies varies depending on the specific variant of Kaposi's sarcoma such as:
* '''HAART therapy regimens recommended for the management of Kaposi's sarcoma patients may include:'''
:* Classic Kaposi's sarcoma managemenet may range from no treatment to either radiotherapy, local therapeutic  interventions, or surgical excision.
:* Non nucleoside reverse transcriptase (NNRT)-based therapy
:* Iatrogenic Kaposi's sarcoma management focuses on modifying immunosuppressive therapy in addition to local therapeutic interventions.
:* Protease Inhibitor (PI)-based therapy
:* Endemic Kaposi's sarcoma is primarily manage by systemic chemotherapy
 
:* There is no curative treatment for epidemic Kaposi's sarcoma; the mainstay management is HAART therapy which aims for the palliation and control of Kaposi's sarcoma progression.
* '''Chemotherapy regimens recommended for the management of Kaposi's sarcoma patients may include:'''
:* Liposomal anthracyclins
:* Paclitaxel
:* Oral etoposide
:* Doxorubicin {{and}} bleomycin {{and}} vincristine
:* Doxorubicin {{and}} bleomycin {{and}} vinblastine
 
* '''Immune modulators recommended for the management of Kaposi's sarcoma patients may include:'''
:* Interferon-alpha
 
* '''Targeted therapies recommended for the management of Kaposi's sarcoma patients may include:'''
:* Antiherpes therapy
:* Angiogenic inhibitors (e.g., thalidomide)
:* VEGF inhibitors
:* Tyrosine kinase inhibitors
:* Matrix metalloproteinases

Revision as of 19:01, 21 January 2016

  • Local/regional therapy recommended for the management of Kaposi's sarcoma patients may include:
  • Surgical excision
  • Cryotherapy
  • Sclerotherapy
  • Intralesional vinca-alkaloids, bleomycin, and interferon-alpha
  • Topical 0.1% alitretinoin
  • Imiquimod cream
  • Radiotherapy
  • Laser therapy
  • HAART therapy regimens recommended for the management of Kaposi's sarcoma patients may include:
  • Non nucleoside reverse transcriptase (NNRT)-based therapy
  • Protease Inhibitor (PI)-based therapy
  • Chemotherapy regimens recommended for the management of Kaposi's sarcoma patients may include:
  • Liposomal anthracyclins
  • Paclitaxel
  • Oral etoposide
  • Doxorubicin AND bleomycin AND vincristine
  • Doxorubicin AND bleomycin AND vinblastine
  • Immune modulators recommended for the management of Kaposi's sarcoma patients may include:
  • Interferon-alpha
  • Targeted therapies recommended for the management of Kaposi's sarcoma patients may include:
  • Antiherpes therapy
  • Angiogenic inhibitors (e.g., thalidomide)
  • VEGF inhibitors
  • Tyrosine kinase inhibitors
  • Matrix metalloproteinases
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:_Kaposi_2&oldid=1204839"